Total Funding
21
57
Total FundingVenture - Series Unknown raised
Growth Score
-32 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
83842
MedTech company focused on neurodegenerative diseases
- Guillaume Blivet: Chief Innovation Officer and FounderPast Role: REGEnLIFE, CEO, President, and Founder
About the Company
REGEnLIFE develops a cutting-edge photomedical neurotechnology for the treatment of neurodegenerative diseases. REGEnLIFE is a late-stage medical technology company currently focused on the treatment of Alzheimer's disease and mild traumatic brain injury (which can lead to dementia). The medical device is a patented therapeutic solution based
on biophotonics. This non-invasive and painless application targets both the brain and the gut. Recent scientific studies suggest that the brain-gut axis plays a key role in the development of neurodegenerative diseases.
